Showing 2881-2890 of 6036 results for "".
- Eyevance’s Natacyn Now Available for Next-Day Deliveryhttps://modernod.com/news/eyevances-natacyn-now-available-next-day/2478883/Eyevance Pharmaceuticals announced that its anti-fungal ophthalmic medication, Natacyn (natamycin ophthalmic suspension 5%), is now available for next-day delivery. Natacyn, which Eyevance acquired from Novartis in 2019, is indicated for the treatment of fungal blepharitis, conjunctivitis,
- Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Programhttps://modernod.com/news/clearside-biomedical-announces-cls-ax-presentation-delivered-at-angiogenesis-exudation-and-degeneration-2021-program/2478874/Clearside Biomedical announced that David M. Brown, MD, delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Ba
- Roche’s Actemra Reduces Deaths in Hospitalized COVID-19 Patients: Studyhttps://modernod.com/news/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/2478863/New findings released Thursday from the ongoing RECOVERY trial showed that Roche’s arthritis drug Actemra (tocilizumab) significantly reduced mortality among patients hospitalized with severe COVID-19, according to researchers leading the study at the University of Oxford. The intravenous I
- Focus Vitamins Unveils New Blue Light Product to Help Protect Eyes from Digital Devices and Eye Fatiguehttps://modernod.com/news/focus-vitamins-unveils-new-blue-light-product-to-help-protect-eyes-from-digital-devices-and-eye-fatigue/2478855/Covalent Medical, owner of the brand “Focus Vitamins,” announced today that their new Blue Light mango-flavored gummy will be available to their partner physician practices for resale. “The B.L.U.E. study shows using electronic digital devices can cause eye fatigue, and even interrupt slee
- Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/2478849/Ocugen and Bharat Biotech announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s Covaxin, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Under th
- Euclid Systems Announces Expansion of Leadership Teamhttps://modernod.com/news/euclid-systems-announces-expansion-of-leadership-team/2478845/Euclid Systems has announced expansion of its leadership team. Joseph Boorady, OD, FAAO, appointed to the position of president and chief executive officer in January 2020, brings over 25 years of experience in the ophthalmic industry as an eye care professional, educational leader, entrepreneur
- JCRS Publishes Phase 2 Nepafenac Clinical Trial With Evolute Sustained Drug Delivery Systemhttps://modernod.com/news/jcrs-publishes-phase-2-nepafenac-clinical-trial-with-evolute-sustained-drug-delivery-system/2478843/Mati Therapeutics announced that a peer reviewed manuscript of a phase 2 clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery
- Gemini Therapeutics Debuts as Publicly Traded Company Focused on Age-Related Macular Degenerationhttps://modernod.com/news/gemini-therapeutics-debuts-as-publicly-traded-company-focused-on-age-related-macular-degeneration/2478841/Gemini Therapeutics announced the completion of its business combination with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics, the resulting combined company, will commence trading its shares today on the Nasdaq Global Market u
- Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Designhttps://modernod.com/news/aldeyra-therapeutics-announces-phase-3-tranquility-dry-eye-disease-trial-design/2478835/Aldeyra Therapeutics announced the finalization of the design of the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry
- GSK, CureVac Partner to Develop mRNA Vaccines for COVID-19 Variantshttps://modernod.com/news/gsk-curevac-partner-to-develop-mrna-vaccines-for-covid-19-variants/2478831/GlaxoSmithKline entered into a new collaboration with CureVac to develop a multi-valent mRNA candidate vaccine to address multiple emerging variants of COVID-19, the companies announced Wednesday. “We believe that next-generation vaccines will be crucial in the continued fight against COVID